6Q0S

Crystal Structure of RSV strain B18537 Prefusion-stabilized glycoprotein F Variant DS-Cav1

Summary for 6Q0S

• Entry DOI: 10.2210/pdb6q0s/pdb
• Descriptor: Fusion glycoprotein F0, 2-acetamido-2-deoxy-beta-D-glucopyranose, SULFATE ION, ... (4 entities in total)
• Functional Keywords: respiratory syncytial virus, structure-based vaccine design, immune system
• Biological source: Human respiratory syncytial virus (subgroup B / strain 18537)
• Total number of polymer chains: 1
• Total formula weight: 62037.72

Authors

Joyce, M.G.,Bao, A.,Kwong, P.D. (deposition date: 2019-08-02, release date: 2020-01-22, Last modification date: 2024-10-23)

Primary citation

Joyce, M.G.,Bao, A.,Chen, M.,Georgiev, I.S.,Ou, L.,Bylund, T.,Druz, A.,Kong, W.P.,Peng, D.,Rundlet, E.J.,Van Galen, J.G.,Wang, S.,Yang, Y.,Zhang, B.,Chuang, G.Y.,McLellan, J.S.,Graham, B.S.,Mascola, J.R.,Kwong, P.D.
Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.
Pathog Immun, 4:294-323, 2019

PubMed Abstract: Respiratory syncytial virus (RSV) subtypes, A and B, co-circulate in annual epidemics and alternate in dominance. We have shown that a subtype A RSV fusion (F) glycoprotein, stabilized in its prefusion conformation by DS-Cav1 mutations, is a promising RSV-vaccine immunogen, capable of boosting RSV-neutralizing titers in healthy adults. In both humans and vaccine-tested animals, neutralizing titers elicited by this subtype A DS-Cav1 immunogen were ~ 2- to 3-fold higher against the homologous subtype A virus than against the heterologous subtype B virus.

PubMed: 31893251
DOI: 10.20411/pai.v4i2.338

Experimental method

X-RAY DIFFRACTION (1.94 Å)